IN2014MN02106A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN02106A IN2014MN02106A IN2106MUN2014A IN2014MN02106A IN 2014MN02106 A IN2014MN02106 A IN 2014MN02106A IN 2106MUN2014 A IN2106MUN2014 A IN 2106MUN2014A IN 2014MN02106 A IN2014MN02106 A IN 2014MN02106A
- Authority
- IN
- India
- Prior art keywords
- compound
- formula
- disclosed
- preparation
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229930195695 Halichondrin Natural products 0.000 abstract 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 abstract 1
- 229960003649 eribulin Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618004P | 2012-03-30 | 2012-03-30 | |
| US201261647127P | 2012-05-15 | 2012-05-15 | |
| PCT/CA2013/050254 WO2013142999A1 (en) | 2012-03-30 | 2013-03-28 | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02106A true IN2014MN02106A (OSRAM) | 2015-09-11 |
Family
ID=49258019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2106MUN2014 IN2014MN02106A (OSRAM) | 2012-03-30 | 2013-03-28 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9278979B2 (OSRAM) |
| EP (1) | EP2831082B1 (OSRAM) |
| JP (1) | JP6531911B2 (OSRAM) |
| CN (1) | CN104334562A (OSRAM) |
| AU (1) | AU2013239290B2 (OSRAM) |
| CA (1) | CA2868627C (OSRAM) |
| IN (1) | IN2014MN02106A (OSRAM) |
| WO (1) | WO2013142999A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1771431A1 (en) | 2004-06-03 | 2007-04-11 | Eisai Co., Ltd. | Intermediates for the preparation of halichondrin b |
| JP5735277B2 (ja) | 2007-10-03 | 2015-06-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハリコンドリンｂ類似体の合成のための中間体および方法 |
| EP2528914B1 (en) | 2010-01-26 | 2014-06-11 | Eisai R&D Management Co., Ltd. | Furo[3,2-b]pyrane derivatives useful in the synthesis of halichondrin b analogs |
| EP2785687B1 (en) | 2011-11-30 | 2019-02-20 | Sandoz AG | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
| JP2015501818A (ja) | 2011-12-16 | 2015-01-19 | アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． | ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法 |
| WO2013097042A1 (en) | 2011-12-29 | 2013-07-04 | Alphora Research Inc. | 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation |
| WO2015000070A1 (en) * | 2013-07-03 | 2015-01-08 | Alphora Research Inc. | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups |
| CN103483352A (zh) * | 2013-10-18 | 2014-01-01 | 李友香 | 抗肿瘤的药用原料药 |
| JP6625533B2 (ja) * | 2013-11-04 | 2019-12-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハリコンドリンｂの類縁体の合成において有用な大環化反応および中間体 |
| JP6443812B2 (ja) | 2013-12-06 | 2018-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハリコンドリンｂ類縁体の合成に有用な方法 |
| TW201617326A (zh) | 2014-03-06 | 2016-05-16 | Ａｌｐｈｏｒａ研發股份有限公司 | （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物 |
| JP2017520586A (ja) | 2014-06-30 | 2017-07-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ハリコンドリン類似体の合成およびその使用 |
| CN105713031B (zh) * | 2014-12-05 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 一种用于制备艾日布林的中间体及其制备方法 |
| US10344038B2 (en) | 2015-04-30 | 2019-07-09 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
| CN112250692B (zh) | 2015-05-07 | 2023-08-29 | 卫材R&D管理有限公司 | 可用于合成软海绵素大环内酯的大环化反应以及中间体和其他片段 |
| WO2017139664A1 (en) | 2016-02-12 | 2017-08-17 | Eisai & R&D Management Co., Ltd. | Intermediates in the synthesis of eribulin and related methods of synthesis |
| MD3423105T2 (ro) | 2016-03-02 | 2021-10-31 | Eisai R&D Man Co Ltd | Conjugați anticorp-medicament pe bază de eribulină și metode de utilizare |
| CN109415383A (zh) * | 2016-05-26 | 2019-03-01 | 雷迪博士实验室有限公司 | 制备艾日布林的方法及其中间体 |
| CN109641917B (zh) | 2016-06-30 | 2022-06-14 | 卫材R&D管理有限公司 | 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体 |
| JP6978758B2 (ja) | 2016-11-11 | 2021-12-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | パラジウム媒介ケトール化 |
| CN110167536A (zh) | 2016-11-23 | 2019-08-23 | 雷迪博士实验室有限公司 | 艾日布林及其中间体的制备方法 |
| CN108658956B (zh) * | 2017-03-28 | 2021-02-02 | 上海时莱生物技术有限公司 | 艾日布林中间体及其制备方法 |
| IL288991B2 (en) | 2017-04-05 | 2023-12-01 | Harvard College | Macrocyclic compound and uses thereof |
| US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
| CN108948064B (zh) * | 2017-05-17 | 2021-02-02 | 上海时莱生物技术有限公司 | 一种艾日布林中间体及其制备方法 |
| WO2018217894A1 (en) * | 2017-05-24 | 2018-11-29 | Eisai R&D Management Co., Ltd. | Fluorine-labelled halichondrin derivatives and related methods of synthesis |
| US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
| CA3211559A1 (en) | 2017-07-06 | 2019-01-10 | President And Fellows Of Harvard College | Synthesis of halichondrins |
| JP7353281B2 (ja) | 2017-11-15 | 2023-09-29 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 大環状化合物およびそれらの使用 |
| KR102799793B1 (ko) * | 2018-01-03 | 2025-04-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 화합물 |
| IL279168B (en) | 2020-12-02 | 2022-04-01 | Finetech Pharmaceutical Ltd | A process for the preparation of eribulin |
| CN114213429B (zh) * | 2021-12-22 | 2023-06-20 | 苏州正济药业有限公司 | 一种甲磺酸艾立布林杂质的制备方法 |
| KR20250133788A (ko) * | 2023-01-17 | 2025-09-08 | 시스트이뮨, 인코포레이티드 | 에리불린 약물 접합체 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338865A (en) | 1992-03-12 | 1994-08-16 | President And Fellows Of Harvard College | Synthesis of halichondrin B and norhalichondrin B |
| US5436238A (en) | 1992-03-12 | 1995-07-25 | President And Fellows Of Harvard College | Halichondrins and related compounds |
| ATE191712T1 (de) | 1993-07-09 | 2000-04-15 | Theramex | Neue strukturelle vitamin d derivate |
| EP2277873B1 (en) | 1998-06-17 | 2012-05-30 | Eisai R&D Management Co., Ltd. | Intermediate compound for the preparation of halichondrin analogs |
| US7001982B2 (en) | 2003-03-31 | 2006-02-21 | Council Of Scientific And Industrial Research | Non-natural C-linked carbo-β-peptides with robust secondary structures |
| EP1771431A1 (en) | 2004-06-03 | 2007-04-11 | Eisai Co., Ltd. | Intermediates for the preparation of halichondrin b |
| US20060045846A1 (en) * | 2004-08-30 | 2006-03-02 | Horstmann Thomas E | Reagents and methods for labeling terminal olefins |
| WO2009124237A1 (en) * | 2008-04-04 | 2009-10-08 | Eisai R&D Management Co., Ltd. | Halichondrin b analogs |
| EP2785687B1 (en) | 2011-11-30 | 2019-02-20 | Sandoz AG | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
| JP2015501818A (ja) | 2011-12-16 | 2015-01-19 | アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． | ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法 |
| WO2013097042A1 (en) | 2011-12-29 | 2013-07-04 | Alphora Research Inc. | 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation |
| WO2014183211A1 (en) | 2013-05-15 | 2014-11-20 | Alphora Research Inc. | 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof |
-
2013
- 2013-03-28 US US14/389,439 patent/US9278979B2/en not_active Expired - Fee Related
- 2013-03-28 EP EP13769493.1A patent/EP2831082B1/en not_active Not-in-force
- 2013-03-28 WO PCT/CA2013/050254 patent/WO2013142999A1/en not_active Ceased
- 2013-03-28 AU AU2013239290A patent/AU2013239290B2/en not_active Ceased
- 2013-03-28 JP JP2015502027A patent/JP6531911B2/ja not_active Expired - Fee Related
- 2013-03-28 CA CA2868627A patent/CA2868627C/en active Active
- 2013-03-28 IN IN2106MUN2014 patent/IN2014MN02106A/en unknown
- 2013-03-28 CN CN201380028907.2A patent/CN104334562A/zh active Pending
-
2016
- 2016-02-04 US US15/015,161 patent/US9695187B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6531911B2 (ja) | 2019-06-19 |
| EP2831082B1 (en) | 2019-02-20 |
| US20150065733A1 (en) | 2015-03-05 |
| US20160152631A1 (en) | 2016-06-02 |
| WO2013142999A1 (en) | 2013-10-03 |
| AU2013239290A1 (en) | 2014-10-30 |
| CN104334562A (zh) | 2015-02-04 |
| AU2013239290B2 (en) | 2017-08-03 |
| US9278979B2 (en) | 2016-03-08 |
| CA2868627C (en) | 2021-02-16 |
| EP2831082A4 (en) | 2016-01-06 |
| US9695187B2 (en) | 2017-07-04 |
| JP2015512897A (ja) | 2015-04-30 |
| CA2868627A1 (en) | 2013-10-03 |
| EP2831082A1 (en) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02106A (OSRAM) | ||
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| IN2014MN01521A (OSRAM) | ||
| IN2014MN02598A (OSRAM) | ||
| NZ729037A (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| TN2011000400A1 (en) | Inhibitors of beta-secretase | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| PH12015502839A1 (en) | Antiviral compounds | |
| TN2014000357A1 (en) | Heterocyclyl compounds | |
| MY175854A (en) | Novel quinolone derivatives | |
| EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
| IN2014MN02459A (OSRAM) | ||
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
| IN2014CN04530A (OSRAM) | ||
| IN2015DN01119A (OSRAM) | ||
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| PH12016500885A1 (en) | Novel heterocyclic compounds | |
| PH12016500394A1 (en) | Polymorphic form of pyrrole derivative and intermediate thereof | |
| IN2012DN02502A (OSRAM) | ||
| MX390763B (es) | Compuestos de tetraciclina | |
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. |